Pigs in Transplantation Research and Their Potential as Sources of Organs in Clinical Xenotransplantation

• Published in: Comparative medicine 2024-04, Vol.74 (2), p.33-48
• Main Authors: Raza, S Sikandar, Hara, Hidetaka, Eyestone, Willard, Ayares, David, Cleveland, David C, Cooper, David K C
• Format: Article
• Language: English
• ISSN: 1532-0820
• DOI: 10.30802/AALAS-CM-23-000030

The pig has long been used as a research animal and has now gained importance as a potential source of organs for clinical xenotransplantation. When an organ from a wild-type (i. e., genetically unmodified) pig is transplanted into an immunosuppressed nonhuman primate, a vigorous host immune response causes hyperacute rejection (within minutes or hours). This response has been largely overcome by 1) extensive gene editing of the organ-source pig and 2) the administration to the recipient of novel immunosuppressive therapy based on blockade of the CD40/CD154 T cell costimulation pathway. Gene editing has consisted of 1) deletion of expression of the 3 known carbohydrate xenoantigens against which humans have natural (preformed) antibodies and 2) the introduction of human 'protective' genes. The combination of gene editing and novel immunosuppressive therapy has extended life-supporting pig kidney graft survival to greater than 1 y and of pig heart survival to up to 9 mo. This review briefly describes the techniques of gene editing, the potential risks of transfer of porcine endogenous retroviruses with the organ, and the need for breeding and housing of donor pigs under biosecure conditions.